KRIBIOLISA™ Anti-Ranibizumab (Lucentis) ELISA

SKU: KBI2029 Category:

58,000.00

Enzyme Immunoassay for the quantitative determination of Anti-Ranibizumab antibodies in serum, plasma and cell culture supernatant.

Key features:
1. Quantitative estimation of anti-drug antibodies
2. Validated as per international bioassay validation guidelines
3. Recovery: 80-120%
4. Precision CV <10%


Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells



Description

Introduction:
Ranibizumab (Lucentis) is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). VEGF is a biochemical signal protein that promotes angiogenesis throughout the body and in the eye. Through binding to VEGF-A, ranibizumab interrupts the interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels. AntiDrug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Ranibizumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects Anti-Ranibizumab antibodies and may be used for monitoring immunogenicity.

Intended Use:
The KRIBIOLISA Anti-Ranibizumab ELISA is used as an analytical tool for quantitative determination of Anti-Ranibizumab antibodies in serum, plasma and cell culture supernatant.

Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Ranibizumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Ranibizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Ranibizumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Ranibizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.










If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward

Additional information

Species

Human

Biomarker Estimation

measures antibodies to the drug

Sample Type

Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul)

Calibration Range

10 ng/ml – 640 ng/ml

Sensitivity

10 ng/ml

Detection Method

Colorimetric

Regulatory Status

Research Use Only

Research Area

Inflammation

Entez Gene ID

RG-3645 Human

Alternate Names / Synonyms

Ranibizumab, rhuFab V2

Alternate Drug Brand Names

Byooviz, Cimerli, Lucentis, Susvimo

Drug Bank Accession Number

DB01270

ELISA Type

Direct Sandwich Assay

Storage Temperature

Store the unopened product at 2-8 Deg C. Opened products to be stored as per temperatures indicated on the datasheet.

Validation

The kit has been validated against international bioassay validation guidelines. Refer to the IFU for more details.

Disclaimer

Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only.